Study of APD421 With and Without Ondansetron

Postoperative Nausea and Vomiting Clinical Trial

Official title:

A Randomised, Double-blind, Placebo-controlled, Crossover Study in Healthy Adult Subjects to Investigate the Effect of Intravenous APD421, With and Without Ondansetron, on Cardiac Conduction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03583489
• Other study ID #: DP10022
• Status: Completed
• Phase: Phase 1
• Start date: July 17, 2018
• Est. completion date: August 13, 2018

Study information

• Verified date: September 2018
• Source: Acacia Pharma Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Collection of pharmacokinetic and electrocardiograph data from healthy volunteers given APD421 +/- ondansetron

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 13, 2018
• Est. primary completion date: August 13, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Healthy subjects

2. Age 18 to 65 years of age at time of signing ICF

3. Body mass index (BMI) of 18 to 30 kg/m2

4. Must be willing and able to communicate and participate in the whole study

5. Must provide written informed consent

6. Must agree to use an adequate method of contraception

Exclusion Criteria:

1. Subjects who have received any investigational medicinal product (IMP) in a clinical research study within the 3 months prior to IMP administration on this study

2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee

3. Subjects who have previously been enrolled in this study

4. Women who are pregnant or breastfeeding

5. Subjects who have received amisulpride for any indication within the previous 4 weeks

6. Allergy to amisulpride or any of the excipients of APD421 or ondansetron

7. History of any drug or alcohol abuse in the past 2 years

8. Regular alcohol consumption >21 units per week

9. Current smokers and those who have smoked within the last 12 months; this includes cigarettes, e-cigarettes and nicotine replacement products (current smoking may be assessed by a validated technique such as urine or serum cotinine levels)

10. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening

11. History of epilepsy

12. History of clinically significant syncope

13. Family history of sudden death

14. Family history of premature cardiovascular death

15. Clinically significant history or family history of congenital long QT syndrome (e.g. Romano-Ward syndrome, Jervell and Lange-Nielson syndrome) or Brugada's syndrome

16. History of clinically significant arrhythmias or ischaemic heart disease (especially ventricular arrhythmias, atrial fibrillation (AF), recent conversion from AF or coronary spasm)

17. Conditions predisposing the volunteer to electrolyte imbalances (e.g. altered nutritional states, chronic vomiting, anorexia nervosa, bulimia nervosa)

18. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes.

This includes subjects with any of the following at screening:

• Absence of regular supraventricular rhythm

• Clinically significant PR (PQ) interval prolongation

• Intermittent second or third degree AV block

• Incomplete or complete bundle branch block.

• Abnormal T-wave morphology

• Prolonged QTcB >450 ms or shortened QTcB < 350 ms or family history of long QT syndrome Subject with borderline deviations from these criteria may be included if the deviations do not pose a safety risk, as judged by the investigator

19. Clinically significant abnormal biochemistry, haematology or urinalysis at screening as judged by the investigator, especially:

• Creatinine clearance (estimated using Cockcroft-Gault formula) < 60 mL/min

• Alanine aminotransferase (ALT) > 1.5 x upper limit of normal or bilirubin > 3 x upper limit of normal

20. Positive drugs of abuse test result

21. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results at screening

22. Donation or loss of greater than 100 mL of blood within the 3 months prior to screening or planned blood donation during the study until after final visit

23. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies in the 14 days before IMP administration

24. Failure to satisfy the investigator of fitness to participate for any other reason

Related Conditions & MeSH terms

• Postoperative Nausea and Vomiting
• Vomiting

Intervention

Drug:
• APD421
10 mg IV
• Placebo
IV
• Ondansetron
4 mg IV

Locations

Country	Name	City	State
United Kingdom	Early Phase Clinical Unit	London

Sponsors (1)

Lead Sponsor	Collaborator
Acacia Pharma Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ddQTcF	Placebo-corrected change-from-baseline QTcF interval	0-6 hours